Upgrade Your Vision
A precise procedure where we make EVO ICL lenses that work in harmony with your natural eyes. It’s a process that takes time, but it is certainly worth the wait.
Here’s how we do it.
Joe Jonas
Joe Jonas dreamed of a day where he could live life uninhibited by his nearsightedness. Joe had the EVO procedure to correct his distance vision. See his story on how he broke free from the hassles of contacts and glasses.
Important Safety Information for EVO/EVO+ ICL
The EVO/EVO+ ICL is designed for the correction/reduction of up to -20 diopters (D) of nearsightedness with up to 6 D of astigmatism for patients who are 21 to 60 years of age and for patients 21 years of age or older who have been treated with an intraocular lens. Implantation of the EVO/EVO+ ICL is a surgical procedure, and as such, carries potentially serious risks. The following represent potential complications/adverse events: additional surgeries, cataract formation, transient or persistent loss of best corrected vision, raised pressure inside the eye, loss of cells on the innermost surface of the cornea, conjunctival irritation, corneal swelling, conjunctival irritation, endophthalmitis (total eye infection), significant glare and/or halos around lights, hyphema (blood in the eye), hypopyon (pus in the eye), eye infection, EVO/EVO+ ICL dislocation, macular edema, non-reactive pupil, pupillary block glaucoma, severe inflammation of the eye, iritis, uveitis, vitreous loss and corneal transplant. Before considering EVO/EVO+ ICL surgery you should have a complete eye examination and talk with your eye care professional about the EVO/EVO+ ICL procedure, especially the potential benefits, risks, and complications. You should discuss the time needed for healing after surgery.
Locale Switcher
Latin America
References
1. Packer M. The Implantable Collamer Lens with a central port: review of the literature. Clin Ophthalmol. 2018;12:2427-2438.
2. Martínez-Plaza E, López-Miguel A, López-de la Rosa A, et al. Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life, Am J Ophthalmol 2021;226:117-125.
3. Packer M. Evaluation of the EVO/EVO+ Sphere and Toric Visian ICL: Six month results from the United States Food and Drug Administration clinical trial. Clin Ophthalmol. 2022;16:1541-53.
4. Parkhurst GD. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clin Ophthalmol. 2016;10:1209-1215.
5. Zhang H, Deng Y, Ma K, Yin H, Tang J. Analysis on the changes of objective indicators of dry eye after implantable collamer lens (ICL) implantation surgery. Graefes Arch Clin Exp Ophthalmol. 2024 Jul; 262(7):2321-2328.
6. Shoja, MR. Besharati, MR. Dry eye after LASIK for myopia: Incidence and risk factors. Eur J of Ophthalmol. 2007; 17(1): pp. 1-6.
7. Lee, Jae Bum et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. J Cataract Refract Surg., Volume 26 , Issue 9 , 1326 - 1331.
8. Parkhurst, G. Psolka, M. Kezirian, G. Phakic intraocular lens implantantion in United States military warfighters: A retrospective analysis of early clinical outcomes of the Visian ICL. J Refract Surg. 2011;27(7):473-481.